Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

Blood

Volumn 116, Issue 25, 2010, Pages 5650-5659

  Tallman, Martin S ^a   Kim, Haesook T ^b   Montesinos, Pau ^c   Appelbaum, Frederick R ^d   De La Serna, Javier ^e   Bennett, John M ^f   Deben, Guillermo ^g   Bloomfield, Clara D ^h   Gonzalez, Jose ⁱ   Feusner, James H ^j   Gonzalez, Marcos ^k   Gallagher, Robert ^l   Gonzalez San Miguel, Jose D ^m   Larson, Richard A ⁿ   Milone, Gustavo ^o   Paietta, Elisabeth ^p   Rayon, Chelo ^q   Rowe, Jacob M ^r   Rivas, Concha ^s   Schiffer, Charles A ^t   Vellenga, Edo ^u   Shepherd, Lois ^v   Slack, James L ^w   Wiernik, Peter H ^x   Willman, Cheryl L ^y   Sanz, Miguel A ^c   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d UNIVERSITY OF WASHINGTON   (United States)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g HOSPITAL JUAN CANALEJO   (Spain)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^k HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^l ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^m HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

ⁿ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^o Fundacion para Combatir La Leucemia   (Argentina)

^p MONTEFIORE MEDICAL CENTER   (United States)

^q HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^r TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^s HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^t WAYNE STATE UNIVERSITY   (United States)

^u UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^v National Cancer Institute of Canada Clinical Trials Group   (Canada)

^w MAYO CLINIC   (United States)

^x NEW YORK MEDICAL COLLEGE   (United States)

^y UNIVERSITY OF NEW MEXICO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IDARUBICIN; MITOXANTRONE; RETINOIC ACID;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVOR; CHILD; CONTROLLED STUDY; DEATH; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROMORPHOLOGY; MORBIDITY; NORTH AMERICA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECURRENCE RISK; REMISSION; SCHOOL CHILD; TUMOR DIFFERENTIATION;

EID: 78650560858     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-288613     Document Type: Article

References (42)

1. Neame PB, Soamboonsrup P, Leber B, et al. Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants. Am J Hematol. 1997;56(3):131-142. (Pubitemid 27486423)
2. Bassan R, Battista R, Viero P, et al. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. Leukemia. 1995;9(2):238-243.
3. Mandelli F, Diverio D, Avvisati G, et al., and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90(3):1014-1021.
4. Rovelli A, Biondi A, Cantu R, et al. Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol. 1992;10(9):1413-1418. (Pubitemid 23059924)
5. Golomb HM, Rowley JD, Vardiman JW, Testa JR, Butler A. "Microgranular" acute promyelocytic leukemia: a distant clinical, ultrastructural, and cytogenetic entity. Blood. 1980;55(2):253-259.
6. Guglielmi C, Martelli MP, Diverio D, et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol. 1998;102(4):1035-1041. (Pubitemid 28410536)
7. Shaft D, Shtalrid M, Berebi A, Catovsky D, Resnitzky P. Ultrastructural characteristics and lysozyme content in hypergranular and variant type of acute promyelocytic leukaemia. Br J Haematol. 1998;103(3):729-739. (Pubitemid 28545309)
8. McKenna RW, Parkin J, Bloomfield CD, Sunberg RD, Brunning RD. Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant. Br J Haematol. 1982;50(2):201-214. (Pubitemid 12165662)
9. Biondi A, Luciano A, Bassan R, et al. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. Leukemia. 1995;9(9):1461-1466.
10. Foley R, Soamboonsrup P, Carter RF, et al. CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/ hypogranular morphology, expression of CD2 and bcr3 isoform. Am J Hematol. 2001;67(1):34-41. (Pubitemid 32336702)
11. Paietta E, Goloubeva O, Neuberg D, et al., and the Eastern Cooperative Oncology Group. A Surrogate marker profile for PML/Rarα expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Clin Cytom. 2004; 59(1):1-9.
12. Gale RE, Hills R, Pizey AR, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106(12):3768-3776.
13. Noguera NI, Breccia M, Divona M, et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia. 2002;16(11):2185-2189.
14. Gallagher RE, Willman CL, Slack JL, et al. Association of PML-RARalpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood. 1997;90(4):1656-1663.
15. Maslak P, Miller WH Jr, Heller G, Scheinberg DA, Dmnitrovsky E, Warrell RP Jr. CD2 expression and PML/RARalpha transcripts in acute promyelocytic leukemia. Blood. 1993;81(6):1666.
16. Douer D, Santillana S, Ramezani L, et al. Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML-RARalpha gene. Br J Haematol. 2003;122(4):563-570.
17. Haferlach T, Kohlmann A, Schnittger S, et al. AML M3 and AML M3Variant have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosomes Cancer. 2005;43(2):113-127.
18. Cunningham I, Gee TS, Reich LM, Kempin SJ, Angelita NN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 1989;73(5):1116-1122.
19. Head D, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood. 1995;86(5):1717- 1728.
20. Sanz MA, Jarque I, Martin G, et al. Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer. 1988;61(1):7-13.
21. Davey FR, Davis RB, MacCallum JM, et al. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol. 1989;30(4):221-227.
22. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94(4):1192-1200.
23. Tallman MS, Andersen JW, Schiffer CA, et al. Alltrans retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021-1028.
24. Tallman MS, Andersen JW, Schiffer CA, et al. Alltrans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup Protocol. Blood. 2002;100(13):4298-4302.
25. Bennett JM, Catovsky D, Daniel MT, et al. A variant form of hypergranular promyelocytic leukemia (M3). Br J Haematol. 1980;44(1):169-170.
26. Liso V, Bennett J. Morphological and cytochemical characteristics of leukaemic promyelocytes. Best Pract Res Clin Haematol. 2003;16(3):349-355. (Pubitemid 41128425)
27. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94(9):3015-3021.
28. Sanz MA, Martin G, Gonzales M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103(4):1237-1243. (Pubitemid 38168633)
29. Sanz M, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA99 multicenter study by the PETHEMA group. Blood. 2008;112(8):3130-3134.
30. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247-1253.
31. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775-783.
32. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
33. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(445):496-509.
34. Reading CL, Estey EH, Huh YO, et al. Expression of unusual immunophenotype combinations in acute promyelocytic leukemia. Blood. 1993;81(11):3083-3090. (Pubitemid 23162129)
35. Claxton DF, Reading CL, Nagarajan L, et al. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood. 1992;80(3):582-586.
36. Au WY, Fung A, Chim CS, et al. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Br J Haematol. 2004;125(3):463-469. (Pubitemid 38916191)
37. Callens C, Chevret S, Cayuela JM, et al, European APL Group. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19(7):1153-1160.
38. Chillon MC, Santamaria C, Garcia-Sanz R. et al. Long FLT3 internal tandem duplications and reduced PML-RARalpha expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. Haematologica. 2010;95(5):745-751.
39. Ghaffari SH, Shayan-Asl N, Jamailahmadi K, et al. Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Ann Oncol. 2008;19(11):1927-1934.
40. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395-3402.
41. Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95(1):90-95. (Pubitemid 30017230)
42. Sohal J, Phan VT, Chan PV, et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood. 2003;101(8):3188-3197. (Pubitemid 36858014)